MannKind | MNKD - 流动负债

金融业

USD

USD 792.18M

现金及等价物

USD 74.88M

USD 33.65M

USD 291.58M

USD 171.03M

USD 119.91M

USD -69.24M

USD 17.92M

407

EPS每股收益

USD 0.01

股本和储备

USD -51.02M

USD 78.31M

债务利息支出

USD 13.87M

USD 2.63M

USD 548.44M

USD 667.9M

USD -15.95M

USD 119.65M

USD -69.24M

普通股股本

USD 307.83M

303.7

USD -20.93M

USD 111.96M

销售和管理费用

USD 29.09M

USD 35.31M

贸易债权人

USD 9.03M

应收帐款人

USD 38.37M

	流动负债	更改		日
Adma Biologics	USD 69.54M		13.05M	2025-12
BioCryst Pharmaceuticals	USD 196.07M		5.83M	2025-12
Eli Lilly	USD 35.23B		4.91B	2025-12
Halozyme Therapeutics	USD 177.09M		660.14M	2025-12
Insmed	USD 468.87M		51.66M	2025-12
Karyopharm Therapeutics	USD 87.16M		12.06M	2025-09
MacroGenics	USD 43.11M		1.36M	2025-12
MannKind	USD 171.03M		61.9M	2025-12
Merck	USD 28.63B		2.59B	2025-09
Minerva Neurosciences	USD 2.29M		381K	2025-12
Novavax	USD 459.95M		30.08M	2025-12
Novo Nordisk	DKK 32.79B		203.33B	2025-06
Pfizer	USD 36.6B		1.13B	2025-09
Sanofi	EUR 28.35B		3.76B	2025-12
Xencor	USD 95.91M		9.42M	2025-12